Severe tachycardia following low-dose clozapine treatment

Australasian Psychiatry

Volumn 13, Issue 1, 2005, Pages 80-82

  Stampfer, Hans ^a   Swanepoel, Peter ^b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

Adverse drug reaction; Clozapine; Tachycardia

Indexed keywords

ANTIBIOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; TEMAZEPAM;

ADULT; ARTICLE; CASE REPORT; CHOLANGITIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG FEVER; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART RATE; HUMAN; LOW DRUG DOSE; NEUTROPHILIA; PARANOID SCHIZOPHRENIA; PROBABILITY; PULSE RATE; SCORING SYSTEM; SLEEP WAKING CYCLE; TACHYCARDIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HUMANS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS, CIRCADIAN RHYTHM; TACHYCARDIA;

EID: 17144392563     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2004.02156.x     Document Type: Article

References (15)

1. Stampfer H. The relationship between psychiatric illness and the circadian pattern of heart rate. Australian and New Zealand Journal of Psychiatry 1998; 32: 187-189.
2. Buckley P, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety 2000; 23: 215-228.
3. Safferman AZ, Lieberman JA, Kane JM, Szymankis S, Kinon B. Update on the clinical efficacy and side effects of clozpine. Schizophrenia Bulletin 1991; 17: 247-261.
4. Lieberman A Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly 1992; 63: 51-70.
5. Rechlin T, Claus D, Weis M. Heart rate variability in schizophrenia patients and changes of autonomic heart rate parameters during treatment with clozapine. Biological Psychiatry 1994; 35 888-892.
6. Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998; 24: 381-390.
7. Miller D. Review and management of clozapine side effects. Journal of Clinical Psychiatry 2000; 61: 14-17.
8. Barak P, Wittenberg N, Naor S, Kutzuk D, Weizman A. Clozapine in elderly psychiatric patients: tolerability, safety and efficacy. Comprehensive Psychiatry 1999: 40: 320-325.
9. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics 1981; 30: 239-245.
10. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine 2001; 345: 224-225.
11. Hasan S, Buckley P. Novel antipsychotic and the neuroleptic malignant syndrome: a review and critique. American Journal of Psychiatry 1998; 155: 1113-1116.
12. Agelink M, Majewski T, Wurthmann C et al. Effects of newer atypical antipsychotics an autonomic neurocardiac function: a comparison between amilsulpride, olanzapine, sertindole and clozapine. Journal of Clinical Psychopharmacology 2001; 21: 8-13.
13. Cohen H, Loewenthal U, Matar M, Kotler M. Heart rate variability in schizophrenic patients treated with antipsychotic agents. Harefua 2001; 140: 1142-1147.
14. Chengappa KN, Pollock BG, Parepally H et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. Journal of Clinical Psychopharmacology 2000; 20: 311-316.
15. Palatini P. Need for a revision of the normal limits of resting heart rate. Hypertension 1999; 33: 622-625.